A Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Agilent Technologies Inc (A) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has positive catalysts, strong analyst support, and a promising long-term growth outlook, despite some short-term financial challenges.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is neutral, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support is at 110.487, and resistance is at 115.354. The stock is trading near its pivot point of 112.921, suggesting limited immediate upside but potential for recovery.
FDA approval for the PD-L1 IHC 22C3 pharmDx diagnostic tool, which reinforces Agilent's leadership in cancer diagnostics.
Analysts maintain a positive outlook, with multiple Buy ratings and price targets ranging from $145 to $
Revenue growth of 6.96% YoY in Q1 2026, supported by the launch of new diagnostic tools.
Decline in net income (-4.09% YoY) and EPS (-3.60% YoY) in Q1
Gross margin dropped by 1.10% YoY, indicating some pressure on profitability.
Bearish moving averages and lack of significant hedge fund or insider trading activity.
In Q1 2026, revenue increased by 6.96% YoY to $1.798 billion, but net income and EPS declined by 4.09% and 3.60%, respectively. Gross margin also dropped slightly to 52.89%. Despite these short-term challenges, the company anticipates future revenue growth driven by its new diagnostic tool.
Analysts are bullish on Agilent, with recent upgrades and Buy ratings. Price targets range from $145 to $185, reflecting confidence in the company's long-term growth potential. Recent upgrades highlight the removal of acquisition overhang and the potential for margin expansion in key markets.
